Lapatinib promotes ovarian cancer cell apoptosis through mROS-HtrA2/Omi pathways

Mitochondria play a pivotal role in regulating the viability of cancer cells. The role of lapatinib in cancer is poorly understood. This study investigated the downstream response to mitochondrial fragmentation using lapatinib to activate mitochondria. In this study cell viability was measured by MTT and LDH leakage assays. Apoptosis was determined by enzyme-linked immunosorbent assay (ELISA) and Annexin V/PI staining. Mitochondrial fragmentation was measured by qPCR and protein expression was detected by Western blot. Results showed that lapatinib increased ovarian cancer cell apoptosis in SKOV-3 cells via triggering mitochondrial fragmentation. Subsequently, mitochondrial fragmentation increased ROS production and facilitated HtrA2/Omi liberation from the mitochondria into the cytoplasm which inturn activated caspase-dependent cell apoptosis. The present results identified the mROS-HtrA2/Omi axis as a novel signaling pathway that is activated by mitochondrial fragmentation and promotes ovarian cancer cell apoptosis with lapatinib treatment.

Ovarian carcinoma; Lapatinib; Mitochondria; mROS-HtrA2/Omi

[1] Munksgaard P.S., Blaakaer J.: “The association between en- dometriosis and ovarian cancer: a review of histological, genetic and molecular alterations”. Gynecol. Oncol., 2012, 124, 164.

[2] Jelovac D., Armstrong D.K.: “Recent Progress in the diagnosis and treatment of ovarian Cancer”. Cancer J. Clin., 2011, 61, 183.

[3] McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al.: “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer”. New Engl. J. Med., 1996, 334, 1.

[4] Li G., Gan Y., Fan Y.: “Enriched environment inhibits mouse pancreatic cancer growth and down-regulates the expression of mitochondria-related genes in cancer cells”. Sci. Rep., 2015, 5, 7856.

[5] Shi C., Cai Y., Li Y.: “Yap promotes hepatocellular carcinoma metastasis and mobilization via governing cofilin/F-actin/lamellipodium axis by regulation of JNK/Bnip3/SERCA/CaMKII pathways”. Redox. Biol., 2018, 14, 59.

[6] Allaway R.J., Wood M.D., Downey S.L.: “Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells”. Oncotarget, 2018, 9, 15860.

[7] Sivaprasadarao A., Abuarab N., Li F.: “TRPM2 channels in mitochondrial dynamics and cancer”. Oncotarget, 2017, 8, 84620.

[8] Xia J., Inagaki Y., Gao J.: “Combination of cinobufacini and doxorubicin increases apoptosis of hepatocellular carcinoma cells through the Fas- and mitochondria-mediated pathways”. Am. J. Chin. Med., 2017, 45, 1537.

[9] Pan L., Zhou L., Yin W., Bai J., Liu R.: “miR-125a induces apop- tosis, metabolism disorder and migrationimpairment in pancreatic cancer cells by targeting Mfn2-related mitochondrial fission”. Int. J. Oncol., 2018, 53, 124.

[10] Zhou H., Wang J., Zhu P.: “NR4A1 aggravates the cardiac microvascular ischemia reperfusion injury through suppressing FUNDC1-mediated mitophagy and promoting Mff-required mito- chondrial fission by CK2alpha”. Basic Res. Cardiol., 2018, 113, 23.

[11] Li H., He F., Zhao X.: “YAP Inhibits the Apoptosis and Migration of Human Rectal Cancer Cells via Suppression of JNK- Drp1-Mitochondrial Fission-HtrA2/Omi Pathways”. Cell. Physiol. Biochem., 2017, 44, 2073.

[12] Burris H.A. 3rd.: “Dual Kinase Inhibition in the Treatment of Breast Cancer: Initial Experience with the EGFR/ErbB-2 Inhibitor Lapatinib”. Oncologist, 2004, 3, 10.

[13] Higa G.M., Abraham J.: “Lapatinib in the treatment of breast cancer”. Exper. Rev. Anticancer. Ther., 2007, 7, 1183.

[14] Huinink W.T., Lane S.R., Ross G.A., Grp I.T.S.: “Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma”. Ann. Oncol., 2004, 15, 100.

[15] Guarneri V., Piacentini F., Barbieri E., Conte P.F.: “Achievements and unmet needs in the management of advanced ovarian cancer”. Gynecol. Oncol., 2010, 117, 152.

[16] Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A., et al.: “Phase III trial of gemcitabine compared with Pegylated liposomal doxorubicin in progressive or recurrent ovarian Cancer”. J. Clin. Oncol., 2008, 26, 890.

[17] Wang H., Zhao X., Ni C., Dai Y., Guo Y.: “Zearalenone regulates endometrial stromal cell apoptosis and migration via the promotion of mitochondrial fission by activation of the JNK/Drp1 pathway”. Mol. Med. Rep., 2018, 17, 7797.

[18] Geng C., Wei J., Wu C.: “Yap-Hippo pathway regulates cerebral hypoxia-reoxygenation injury in neuroblastoma N2a cells via inhibiting ROCK1/F-actin/mitochondrial fission pathways”. Acta Neurol. Belg., 2018.

[19] Fuhrmann D.C., Brune B.: “Mitochondrial composition and function under the control of hypoxia”. Redox. Biol., 2017, 12, 208.

[20] Zhou H., Wang S., Hu S., Chen Y., Ren J.: “ER-Mitochondria Mi- crodomains in Cardiac Ischemia-Reperfusion Injury: A Fresh Per- spective”. Front. Physiol., 2018, 9, 755.

[21] Lei Q., Tan J., Yi S., Wu N., Wang Y., Wu H.: “Mitochonic acid 5 activates the MAPK-ERK-yap signaling pathways to protect mouse microglial BV-2 cells against TNFalpha-induced apoptosis via in- creased Bnip3-related mitophagy”. Cell. Mol. Biol. Lett., 2018, 23, 14.

[22] Zhou H., Hu S., Jin Q.: “Mff-dependent mitochondrial fission contributes to the pathogenesis of cardiac microvasculature ischemia/reperfusion injury via induction of mROS-mediated cardiolipin oxidation and HK2/VDAC1 disassociation-involved mPTP opening”. J. Am. Heart Assoc., 2017, 6, pii: e005328.

[23] Jin Q., Li R., Hu N., Xin T., Zhu P., Hu S., et al.: “DUSP1 alleviates cardiac ischemia/reperfusion injury by suppressing the Mff-required mitochondrial fission and Bnip3-related mitophagy via the JNK pathways”. Redox. Biol., 2018, 14, 576.

[24] Uen W.C., Lee B.H., Shi Y.C., Wu S.C., Tai C.J., Tai C.J.: “Inhibition of aqueous extracts of Solanum nigrum (AESN) on oral cancer through regulation of mitochondrial fission”. J. Tradit. Complement Med., 2018, 8, 220.

[25] Lai Y.J., Tai C.J., Wang C.W., Choong C.Y., Lee B.H., Shi Y.C., et al.: “Anti-Cancer Activity of Solanum nigrum (AESN) through Suppression of Mitochondrial Function and Epithelial-Mesenchymal Transition (EMT) in Breast Cancer Cells”. Molecules. 2016, 21, pii: E553.